Geron Corporation Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
Share: Conference Call Scheduled for 4:30 p.m. ET today Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the fourth quarter and year ended December 31, 2020. The Company ended fiscal year 2020 with $260 million in cash and marketable securities, which is expected to fund operations until the end of 2022. "Geron's vision is to be recognized as a leader in the treatment of hematologic malignancies by changing the course of ...
Source: benzinga.com